Organigram delivered strong Q1 Fiscal 2026 performance with robust net revenue growth, a return to net income, and materially improved adjusted EBITDA driven by Canadian market leadership and growing international sales.

Organigram's Q4 2025 results showed strong revenue growth driven by international sales and acquisitions. However, the company reported a larger net loss due to non-cash fair value adjustments.

Organigram achieved its second consecutive quarter of record revenue in Q3 2025, led by the Motif acquisition, robust international sales, and U.S. market entry. Despite a net loss, the company saw strong adjusted EBITDA and positive free cash flow.